Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Mineralys Therapeutics Inc (MLYS)

211 + Investors. Track Smart Money conviction in MLYS. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -10
Streak
1Q ▼
Buyers last Q
57%

Smart Money Signals — MLYS

Based on 212 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their MLYS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (95% of max)

95% of all-time peak
212 hedge funds hold MLYS right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +38% more funds vs a year ago

fund count last 6Q
+58 new funds entered over the past year (+38% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 57% buying

132 buying98 selling
Last quarter: 132 funds bought or added vs 98 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-22 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 38 → 44 → 53 → 31. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
📌

Mixed — 32% long-term, 33% new

■ 32% conviction (2yr+) ■ 35% medium ■ 33% new
Of the 212 current holders: 68 (32%) held >2 years, 74 held 1–2 years, and 70 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💎

Buying through price weakness — shares +1%, value -25%

Value
-25%
Shares
+1%
Last quarter: funds added +1% more shares while total portfolio value only changed -25%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
➡️

Steady discovery — ~31 new funds/quarter

59 → 38 → 44 → 53 → 31 new funds/Q
New funds entering each quarter: 38 → 44 → 53 → 31. Consistent flow of new institutional buyers without clear acceleration or slowdown.
📊

Mixed cohorts — 32% veterans, 50% new entrants

■ 32% veterans ■ 17% 1-2yr ■ 50% new
Of 226 current holders: 73 (32%) held 2+ years, 39 held 1–2 years, 114 (50%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
✅

Strong quality — 29% AUM from major funds

29% from top-100 AUM funds
46 of 210 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — MLYS

In 2026 Q1, 132 hedge funds were net buyers of MLYS (31 opened a new position, 101 added to an existing one), while 98 reduced or exited (57 trimmed, 41 sold completely) — a 57% buyer ratio, indicating a slight buying edge. 29% of total institutional value in MLYS is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -10 funds (more exits than new entries). Total institutional holders: 212.

Hedge Fund Ownership: MLYS

How many hedge funds hold MLYS — quarterly history vs. share price
Quarterly hedge fund ownership of MLYS vs. share price

Market Analysis: MLYS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: MLYS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Mineralys Therapeutics Inc (MLYS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much MLYS has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 82d ago
MLYS
-9.1%
XLV
+1.9%

MLYS outperformed XLV by -11.0% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 37d ago
MLYS
-10.0%
XLV
+3.0%

Since the filing became public, MLYS outperformed XLV by -13.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

26 top-rated funds 11 high-conviction
Consensus
6.2
/ 10
breadth
×
Elite
4.9
/ 10
conviction
Hedge Fund Positioning: MLYS
211 + Investors

Track Smart Money conviction in MLYS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 211 222 -4.95%
13F Shares 98M 97M 1.11%
Total Value $2.60B $3.47B -25.07%
New Positions 30 53 -23
Increased Positions 99 83 +16
Closed Positions 41 24 +17
Reduced Positions 52 71 -19
Total Calls 8 9 -11.11%
Total Puts 8 8 -
PUT/CALL Ratio 1.0 0.89 Neutral

Statistics: MLYS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

211 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MLYS. Verified SEC 13F-HR filings.

QUARTER:
Top 25 MLYS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Catalys Pacific, LLC 92.81% 7,903,838 $214.1M
2 Andera Partners 24.38% 1,591,917 $43.1M
3 Samsara BioCapital, LLC 15.45% 5,871,018 $159.0M
4 22nw, LP 8.25% 444,325 $12.0M
5 Sphera Funds Management LTD. 5.76% 1,339,971 $36.3M
6 Caligan Partners LP 5.00% 2,772,654 $75.1M
7 Sr One Capital Management, LP 4.63% 1,563,966 $42.4M
8 Buckley Capital Advisors, LLC 3.37% 173,100 $4.7M
9 Davern Capital Partners, LP 3.32% 447,153 $12.1M
10 Stempoint Capital LP 2.81% 533,378 $14.4M
11 Laurion Capital Management LP 2.64% 2,232,040 $60.5M
12 Catalio Capital Management, LP 2.48% 439,041 $11.9M
13 Ra Capital Management, L.P. 2.21% 7,692,750 $208.4M
14 Ishara Investments LP 2.10% 82,000 $2.2M
15 Lion Point Capital, LP 1.70% 10,500 $284K
16 Findell Capital Management LLC 1.60% 202,000 $5.5M
17 Orbimed Advisors LLC 1.10% 2,052,900 $55.6M
18 Troluce Capital Advisors LLC 1.09% 655,000 $17.7M
19 Suvretta Capital Management, LLC 1.06% 1,538,662 $41.7M
20 Parkman Healthcare Partners LLC 1.06% 380,137 $10.3M
21 Affinity Asset Advisors, LLC 1.05% 750,000 $20.3M
22 Integral Health Asset Management, LLC 0.97% 750,000 $20.3M
23 Nantahala Capital Management, LLC 0.89% 895,481 $24.3M
24 Rhenman & Partners Asset Management AB 0.88% 263,071 $7.1M
25 Pale Fire Capital SE 0.87% 365,626 $9.9M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Mineralys Therapeutics Inc (MLYS)

What does the Smart Money Trend signal show for MLYS?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their MLYS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for MLYS?

Slight buying edge — 57% buying: Last quarter: 132 funds bought or added vs 98 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for MLYS holders?

Strong quality — 29% AUM from major funds: 46 of 210 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held MLYS?

Mixed — 32% long-term, 33% new: Of the 212 current holders: 68 (32%) held >2 years, 74 held 1–2 years, and 70 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Mineralys Therapeutics Inc (MLYS) following the 2026 Q1 hedge fund 13F filings?

As of today, MLYS has moved -10.0% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.0% for the XLV sector ETF — an outperformance of -13.0%. Since the quarter end (March 31, 2026), MLYS has gained -9.1% vs +1.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →